Pharmacyte Biotech Inc (OTCMKTS:PMCB) published an educational piece of article to help people learn about the Cell-in-a-Box technology and its role in treatment of pancreatic cancer. The first article is written by the CEO Dr. Gerald W. Crabtree.
The company’s live-cell encapsulation technology, termed as “Cell-in-a-Box®”, does not deliver and encapsulate drugs to cure pancreatic cancer. The term Cell-in-a-Box® is a title given to a technology using which genetically modified living cells of human are encapsulated in protective cocoons. The outer shell is made chiefly of cotton, or more explicitly of cellulose. These capsules or cocoons are not developed to, and cannot be utilized to enclose small molecules.
The capsules feature a diameter of head pin size while the outer shell of capsules has tiny openings in it. The nutrients are entered through these openings so as to feed the live cells within the capsules. These openings are large enough to permit beneficial products and waste products released by the cells to leave the capsule.
However, these openings are extremely small to allow the cells leave the capsule. These cells thrive on the oxygen, nutrients and other molecules supplied by the blood stream. Most prominently, the openings are too small to allow immune system cells enter into the capsules, which if happens can destroy the cells present within the capsule.
Natural Alternatives International, Inc. (NASDAQ:NAII) stated that the net income for the fiscal competed June 30, 2015 came at $3.3 million and net sales were $79.5 million. There was a rise of 3.5% in net sales generated from contract manufacturing segment compared to the prior year. This increase can be attributed to strong sales volumes of products in all the markets.
After recording strong session on Tuesday, the stock price of Nuo Therapeutics Inc (OTCMKTS:NUOT) declined more than 9% in last trading session. The company launched educational program to hemp wound care centers in making the transition to ICD-10.
